Clinical Trial Update: A Safety and MORAb-028 Dose Determination Study in Subjects With Metastatic Melanoma [Phase 1]

View source ↗

Summary

Phase 1 safety and dose-determination study of MORAb-028 in metastatic melanoma has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Drugs mentioned

• MORAb-028 (human IgM monoclonal antibody)

Snippet

Sponsor: Morphotek | Conditions: Metastatic Melanoma, Malignant Metastatic Melanoma | Phase 1 | Status: TERMINATED